Endpoints News· @endpts · X·· 13 天前精选AI 评分70
AI 导读
勃林格殷格翰向中国Sino支付3.58亿美元首付款,引进六款临床前ADC和T细胞衔接器,交易总额最高可达70亿美元。原文未披露各项目具体靶点与里程碑付款安排。
推荐理由
交易结构显示首付款与潜在总额差距悬殊,读者可据此判断中国早期肿瘤管线在跨国药企BD中的定价方式。
正文
Boehringer Ingelheim is paying $358M upfront for six preclinical ADCs and T cell engagers from China's Sino, in a deal that could top $7B. https://endpoints.news/boehringer-ingelheim-strikes-7b-backloaded-adc-tce-cancer-deal-with-chinas-sino/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com